Brightheart

Brightheart specializes in developing application software for ultrasound imaging systems, specifically focused on obstetric and fetal health. Their products include tools for fetal heart monitoring, automated fetal echocardiogram assessments, and AI-based classification software to analyze ultrasound images. These are designed to assist clinicians in evaluating fetal development and diagnosing conditions during pregnancy.

Brightheart is based in the United States, which means their devices are subject to FDA regulations. Since their products fall under Class II classification, they must comply with FDA pathways like 510(k) premarket notifications and the Unique Device Identifier (UDI) system to ensure safety and performance before entering the market. The US regulatory framework directly influences how their software is authorized and listed.

Brightheart’s devices are listed in FDA’s 510(k) premarket notification database and the FDA’s Unique Device Identifier (UDI) system. These registries track authorized medical devices in the US, ensuring transparency about their compliance with FDA requirements. Listing in these databases confirms that their software has undergone the necessary regulatory review for obstetric ultrasound applications.

Brightheart’s products are classified as Class II medical devices by the FDA. This classification applies to software that modifies the performance of ultrasound systems for specialized diagnostic purposes, such as fetal monitoring or automated image analysis. Class II devices require special controls (like 510(k) submissions) to demonstrate safety and effectiveness before commercial distribution, distinguishing them from lower-risk Class I devices.